P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS

書誌詳細
出版年:	HemaSphere
主要な著者:	J. Petiti, F. Itri, C. Fava, D. Cilloni
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2022-06-01
オンライン･アクセス:	http://journals.lww.com/10.1097/01.HS9.0000846860.02787.94

類似資料

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms
著者:: Chunyan Wu, 等
出版事項: (2026-06-01)

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta‐Analysis of Cardiovascular Safety
著者:: Roberta Dunn, 等
出版事項: (2025-02-01)

Myeloproliferative neoplasms
著者:: Nick Cross, (Coordinating Author)
出版事項: (2019-06-01)

Myeloproliferative neoplasms
著者:: Jean-Jacques Kiladjian
出版事項: (2018-06-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
著者:: Luca Malcovati, 等
出版事項: (2014-11-01)

The microenvironment in myeloproliferative neoplasm
著者:: Simón Méndez-Ferrer, 等
出版事項: (2018-06-01)

Spleen in myeloproliferative neoplasms
著者:: Giovanni Barosi
出版事項: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
著者:: Graeme Greenfield, 等
出版事項: (2023-07-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
著者:: Kaveh Tari, 等
出版事項: (2015-04-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
著者:: Sophia S. Lee, 等
出版事項: (2021-08-01)

The Hematopoietic Niche in Myeloproliferative Neoplasms
著者:: Annette H. Schmitt-Graeff, 等
出版事項: (2015-01-01)

Interferons in the treatment of myeloproliferative neoplasms
著者:: Pankit Vachhani, 等
出版事項: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
著者:: Daniel Prins, 等
出版事項: (2020-02-01)

Autoimmunity and the risk of myeloproliferative neoplasms
著者:: Sigurdur Y. Kristinsson, 等
出版事項: (2010-07-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
著者:: Raffaele Landolfi, 等
出版事項: (2011-02-01)

CALR Mutations in Myeloproliferative Neoplasms
著者:: Ken-Hong Lim
出版事項: (2014-06-01)

Calreticulin Mutations in Myeloproliferative Neoplasms
著者:: Noa Lavi
出版事項: (2014-10-01)

Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors
著者:: Cinzia Maria Francini, 等
出版事項: (2018-09-01)

S209: TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS
著者:: Sarah Jungius, 等
出版事項: (2023-08-01)

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms
著者:: Kaitlyn Shank, 等
出版事項: (2020-03-01)

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
著者:: Joanna Y Lee, 等
出版事項: (2014-01-01)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
著者:: Gregor Hoermann, 等
出版事項: (2015-01-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
著者:: WANG Chen-hui, 等
出版事項: (2007-11-01)

Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis.
著者:: Gunjan D Manocha, 等
出版事項: (2015-01-01)

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML
著者:: Mengdan Liu, 等
出版事項: (2025-08-01)

Molecular basis of myelodysplastic/myeloproliferative neoplasms
著者:: Andreas Reiter, 等
出版事項: (2009-12-01)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
著者:: Stefan N. Constantinescu, 等
出版事項: (2021-06-01)

Blood cell activation in myeloproliferative neoplasms
著者:: Francisco Cervantes, 等
出版事項: (2009-11-01)

Omalizumab alleviates pruritus in myeloproliferative neoplasms
著者:: Anna Ravn Landtblom, 等
出版事項: (2023-01-01)

Epigenetics and mutations in chronic myeloproliferative neoplasms
著者:: Alessandro M. Vannucchi, 等
出版事項: (2011-10-01)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
著者:: Stephen E. Langabeer PhD, FRCPath
出版事項: (2023-06-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
著者:: Sylvie Hermouet, 等
出版事項: (2023-05-01)

Are Myeloproliferative Neoplasms‐Unclassifiable Really Unclassifiable?
著者:: Giovanni Barosi, 等
出版事項: (2026-04-01)

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms
著者:: Clodagh Keohane, 等
出版事項: (2015-09-01)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
著者:: Ziqi Wan, 等
出版事項: (2020-10-01)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
著者:: I. C. Casetti, 等
出版事項: (2022-06-01)

The aetiology and burden of myeloproliferative neoplasms in the United Kingdom: the MyelOproliferative neoplasmS: an In-depth case-control (MOSAICC) study protocol
著者:: Nouf Abutheraa, 等
出版事項: (2023-12-01)

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
著者:: Costanza Bogani, 等
出版事項: (2013-01-01)

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
著者:: Roopa Dixith, 等
出版事項: (2019-01-01)

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series
著者:: Pusem Patır, 等
出版事項: (2024-06-01)